PT3096779T - Composições e métodos para tratamento de hemorragia intracerebral - Google Patents

Composições e métodos para tratamento de hemorragia intracerebral

Info

Publication number
PT3096779T
PT3096779T PT157085788T PT15708578T PT3096779T PT 3096779 T PT3096779 T PT 3096779T PT 157085788 T PT157085788 T PT 157085788T PT 15708578 T PT15708578 T PT 15708578T PT 3096779 T PT3096779 T PT 3096779T
Authority
PT
Portugal
Prior art keywords
compositions
methods
intracerebral hemorrhage
treating intracerebral
treating
Prior art date
Application number
PT157085788T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT3096779T publication Critical patent/PT3096779T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT157085788T 2014-01-24 2015-01-15 Composições e métodos para tratamento de hemorragia intracerebral PT3096779T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24

Publications (1)

Publication Number Publication Date
PT3096779T true PT3096779T (pt) 2020-02-21

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157085788T PT3096779T (pt) 2014-01-24 2015-01-15 Composições e métodos para tratamento de hemorragia intracerebral

Country Status (18)

Country Link
US (2) US20160375109A1 (OSRAM)
EP (1) EP3096779B1 (OSRAM)
JP (1) JP6624787B2 (OSRAM)
KR (3) KR20160093731A (OSRAM)
CN (2) CN105934250A (OSRAM)
AU (1) AU2015208819B2 (OSRAM)
BR (1) BR112016014617A2 (OSRAM)
CA (1) CA2937418A1 (OSRAM)
DK (1) DK3096779T3 (OSRAM)
ES (1) ES2772802T3 (OSRAM)
HU (1) HUE047588T4 (OSRAM)
IL (1) IL246637A0 (OSRAM)
MX (1) MX375355B (OSRAM)
PL (1) PL3096779T3 (OSRAM)
PT (1) PT3096779T (OSRAM)
RU (1) RU2016126423A (OSRAM)
SI (1) SI3096779T1 (OSRAM)
WO (1) WO2015110939A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150103205A (ko) 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법
SG11201601221XA (en) 2013-09-24 2016-04-28 Pfizer Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570330A1 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care A/S Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
CN101918025A (zh) * 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
JP6163304B2 (ja) * 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9371522B2 (en) * 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
SG11201500579SA (en) * 2012-07-25 2015-02-27 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof
KR20150103205A (ko) * 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
CN105934250A (zh) 2016-09-07
IL246637A0 (en) 2016-08-31
JP6624787B2 (ja) 2019-12-25
ES2772802T3 (es) 2020-07-08
SI3096779T1 (sl) 2020-03-31
RU2016126423A (ru) 2018-03-01
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
EP3096779B1 (en) 2019-12-18
DK3096779T3 (da) 2020-02-24
CN112156176A (zh) 2021-01-01
RU2016126423A3 (OSRAM) 2018-03-01
US20190231856A1 (en) 2019-08-01
CA2937418A1 (en) 2015-07-30
BR112016014617A2 (pt) 2017-09-19
US20160375109A1 (en) 2016-12-29
WO2015110939A1 (en) 2015-07-30
KR20180014221A (ko) 2018-02-07
MX2016009665A (es) 2016-11-14
KR20160093731A (ko) 2016-08-08
AU2015208819A1 (en) 2016-06-30
EP3096779A1 (en) 2016-11-30
HUE047588T4 (hu) 2020-06-29
JP2015147764A (ja) 2015-08-20
HUE047588T2 (hu) 2020-04-28
AU2015208819B2 (en) 2020-01-23
MX375355B (es) 2025-03-04

Similar Documents

Publication Publication Date Title
GB2535253B (en) Compositions and methods
SG10202109655VA (en) Compositions and methods for immunooncology
IL251721A0 (en) Preparations and methods for the treatment of diseases of the central nervous system
PT3490582T (pt) Composições para utilização no tratamento da mielofibrose
LT3206493T (lt) Kompozicijos ir būdai, skirti cns sutrikimams gydyti
AP2017009674A0 (en) Methods and compositions for treating ulcers
ME03749B (me) KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a
IL251759A0 (en) Preparations and methods for treating insomnia
SMT202100273T1 (it) Metodi e composizioni per il trattamento del cancro
IL250715A0 (en) Preparations and methods for the treatment of cultural disorders
LT3189074T (lt) Kompozicijos ir būdai skirti uždegimo gydymui ir prevencijai
IL246879A0 (en) Preparations of Epilimod and methods of using them
IL254963A0 (en) Preparations and methods for the treatment of autism
ZA201703771B (en) Compositions and methods for treating hyperkalemia
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
PL3220908T3 (pl) Kompozycje i sposoby leczenia endometriozy
IL253220A0 (en) Preparations and methods for the treatment of glaucoma
ZA201605109B (en) Compositions and methods for treating neutropenia
IL246637A0 (en) Preparations and methods for the treatment of intracerebral hemorrhage
IL252707B (en) Compositions and methods for treating diseases
GB201402915D0 (en) Compositions and methods
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201407949D0 (en) Compositions and methods for treating biofilms
GB201421947D0 (en) Elecroplating method and composition
GB201403212D0 (en) Compositions and methods